安裝中文字典英文字典辭典工具!
安裝中文字典英文字典辭典工具!
|
- NurExone - From acute injury to functional recovery
NurExone chose to base its ultimate drug delivery platform on exosomes-nanosized extracellular vesicles-due to their natural ability to reach inflamed or damaged tissue By loading exosomes with therapeutic compounds, nanodrugs are created having natural regenerative properties and therapeutic impact
- NurExone Advances U. S. Growth Strategy with Acceptance into - GlobeNewswire
TORONTO and HAIFA, Israel, June 20, 2025 (GLOBE NEWSWIRE) -- NurExone Biologic Inc (TSXV: NRX) (OTCQB: NRXBF) (FSE: J90) (“NurExone” or the “Company”), a biotech company developing
- NurExone Advances U. S. Growth Strategy with Acceptance into Prestigious . . .
NurExone’s acceptance into the prestigious HTH Accelerator Program will support the Company’s expansion into the U S market following the establishment of Exo-top Inc (“Exo-TOP”), the
- 2025-06-20 | NurExone Advances U. S. Growth Strategy with Acceptance . . .
TORONTO and HAIFA, Israel, June 20, 2025 (GLOBE NEWSWIRE) -- NurExone Biologic Inc (TSXV: NRX) (OTCQB: NRXBF) (FSE: J90) (“NurExone CloseCurlyDoubleQuote; or the “Company CloseCurlyDoubleQuote;), a biotech company developing exosome-based therapies for central nervous system injuries, announced today that it has been accepted into the HealthTech Hub (“HTH CloseCurlyDoubleQuote
- NurExone Biologic To Regenerate Nerve Cell Damage - MedicalExpo e-Magazine
Israeli biopharmaceutical firm NurExone Biologic is aiming to change that Its ExoTherapy platform harnesses the healing potential of exosomes—tiny, naturally occurring vesicles that act as cellular messengers, carrying proteins, RNA, and other molecular signals
- A next-generation therapeutic approach for patients after . . . - Nature
Drawing on deep expertise in exosome biology, NurExone has created the ExoTherapy technology platform, which comprises proprietary methods for the production, isolation, and loading of
- Company - NurExone Information Technology; Description
NurExone Biologic Inc is a publicly-traded biopharmaceutical company, listed on the Toronto Stock Exchange (TSXV:NRX), the OTCQB Venture Market (OTCQB:NRXBF) and Frankfurt Stock Exchange (FSE:J90) Developing and commercializing the ExoTherapy platform for production of exosome-loaded nanodrugs
- Nurexone Announces Acute Spinal Cord Injury Trial
ExoPTEN utilizes mesenchymal stem cell-derived exosomes loaded with siRNA targeting PTEN, a molecule that inhibits neural regeneration Preclinical studies in rat models have shown promising results in motor, sensory, and structural recovery after complete spinal cord transection and compression
|
|
|